Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTO0303-C
- Development stage
- Unknown
- Lead developer
- Taejoon Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
**CTO0303-C** is an ophthalmic eye-drop intervention used as the active-comparator arm in Taejoon Pharmaceutical's randomized, double-blind Phase 2b/3 study of pupillary dilation for cycloplegic refraction in pediatric and adolescent participants aged 4 to 15 years. Public trial materials confirm administration as one drop three times at five-minute intervals and assessment of pupil size 30 minutes after dosing, but they do not disclose CTO0303-C's active ingredient, concentration, or molecular pharmacology. ([ctv.veeva.com](https://ctv.veeva.com/study/comparing-efficacy-and-safety-of-cto0303-in-pediatric-subjects))
- Other names
- CTO0303-CCTO-0303-CCTO 0303-C
Beyond the preview
Go deeper on CTO0303-C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTO0303-C.